Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Cancer, rare diseases and neurology targets account for a big chunk of biopharma's buyouts, with interest showing no sign of waning.
Companies with late-stage assets have been attracting ever higher price tags over the past five years, Evaluate Vantage finds.
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
A recent buying spree swells 2021's meagre M&A tally, but the Pfizer-Arena deal could crystallise antitrust concerns.